Biocon Limited board approves QIP at ₹387.74 per share, with issue opening on 12 January 2026 and new oncology biosimilars announced.

S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics Limited to 'BB+' from 'BB' and revised ...

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

Biocon has completed the acquisition of the remaining equity shares of its unlisted subsidiary Biocon Biologics from Mylan ...

Biocon Biologics Limited, a fully integrated, global biosimilars company and subsidiary of Biocon announced that S&P Global Ratings has upgraded the company’s long-term issuer credit rating to ‘BB+’ ...

On Wednesday, Biocon stock slipped 0.55 per cent to settle at Rs 364.55 apiece on the BSE.

On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has approved KIRSTY (insulin aspart-xjhz injection), 100 units ...

Pharma major Biocon is set to announce its Q3FY26 results on 12 Feb 2026. Brokerage reports project a strong Q3FY26 for ...

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process.

Get all latest & breaking news on Biocon Biologics Limited. Watch videos, top stories and articles on Biocon Biologics Limited at moneycontrol.com.

PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug ...